20 June 2025
Futura Medical plc
("Futura" or the "Company")
Notice of Results and Investor Presentation
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, today announces that at its Annual General Meeting, held yesterday at 10:00am BST, the shareholders duly passed all resolutions.
The total number of votes received on each resolution were as follows:
|
| Voting For | Voting Against |
|
| |||||
| Number of votesi | % | Number of votes | % | Total Votes | % ISC | Votes withheldii | |||
| Resolution 1 | To receive and adopt the annual report and accounts for the financial year ended 31 December 2024 | 146,144,976
| 48.12 | 721,656 | 0.24 | 146,866,632
| 48.36 | 261,557 | |
| Resolution 2 | That Harmesh Suniara be and is hereby appointed as a Director of the Company. | 145,681,511
| 47.97 | 1,136,919 | 0.37 | 146,818,430
| 48.34 | 309,759 | |
| Resolution 3 | To re-elect Jeff Needham as a Director of the Company, who retires by rotation in accordance with the Company's articles of association. | 145,170,141
| 47.80 | 1,277,566 | 0.42 | 146,447,707
| 48.22 | 680,482 | |
| Resolution 4 | To re-elect Andrew Unitt as a Director of the Company, who retires by rotation in accordance with the Company's articles of association. | 145,170,141
| 47.80 | 1,277,566 | 0.42 | 146,447,707
| 48.22 | 680,482 | |
| Resolution 5 | To re-appoint Grant Thornton UK LLP as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company. | 146,113,545
| 48.12 | 851,161
| 0.28 | 146,964,706
| 48.40 | 163,483 | |
| Resolution 6 | To authorise the Directors to determine the remuneration of Grant Thornton UK LLP as auditor of the Company. | 145,401,415
| 47.88 | 1,080,802 | 0.36 | 146,482,217
| 48.24 | 645,972 | |
| Resolution 7 | That the Directors be and are generally and unconditionally authorised for the purposes of section 551 Companies Act 2006 to exercise all the powers of the Company to allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company | 144,897,392
| 47.71 | 1,986,162 | 0.65 | 146,883,554
| 48.36 | 244,635 | |
| Resolution 8 iii | Disapplication of pre-emption rights in respect of an additional 20% of the company issued share capital | 144,632,144
| 47.62 | 2,041,210 | 0.67 | 146,673,354
| 48.29 | 454,835 | |
| Resolution 9 iii | To resolve that, subject to the passing of Resolution 8 set out above, the Directors be authorised in addition to any authority granted under Resolution 8 to allot equity securities for cash under the authority given by that resolution as if section 561 of the CA 2006 did not apply to any such allotment or sale | 145,010,004
| 47.75 | 1,860,610 | 0.61 | 146,870,614 | 48.36 | 257,575 | |
i Where shareholders appointed the Chairman as their proxy with discretion as to voting, their votes were cast in favour of the resolution
ii A vote withheld is not a vote in law and is not counted towards the votes cast "For" or "Against" a resolution
iii ⁱSpecial Resolution (75% majority required)
The total voting rights of the Company as at 10:00 am on 17 June 2025 (the time by which shareholders wanting to vote at the AGM were required to be entered on the register) was 303,703,568 ordinary shares of 0.2 pence each. The Company does not hold any shares in treasury.
Contacts:
| Futura Medical plc
| James Barder Chief Executive Officer Angela Hildreth Finance Director and COO
| investor.relations@futuramedical.com +44 (0)1483 685 670
|
| Panmure Liberum Nominated Adviser and Broker
| Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) | +44 (0)20 3100 2000
|
|
| | |
| Alma Strategic Communications | Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock | +44 (0)20 3405 0205 futura@almastrategic.com |
| | | |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.
Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.